Olympus Corporation of the Americas
$5.2M 4,448 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. reported $5,262,421.82 across General Payments, Research, and Ownership to 4,420 physicians and teaching hospitals across 5,730 transactions.
- $5.3M Top quartile payer
- All-tracks total
- 5,730 Top quartile volume
- Transactions
- 4,420 Top quartile reach
- Recipients
- #264
- of 1,925 companies
SpringWorks Therapeutics, Inc. reported $5,262,421.82 across all CMS Open Payments tracks (General + Research + Ownership) to 4,420 physicians and teaching hospitals in Program Year 2024 - ranking #264 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,367,449.50, averaging $1.2K per recipient.
How SpringWorks Therapeutics, Inc.'s $5.3M all-tracks total breaks down
SpringWorks Therapeutics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
55/100
Total payments
D
59/100
Transaction volume
D
52/100
Physician reach
F
44/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer springworks-therapeutics-inc SpringWorks Therapeutics, Inc.
$5.3M · #264/1,925 · 0.0% industry · PY2024
- TOT $5.3M
- RANK #264
- SHARE 0.0%
- TXN 5,730
- RCP 4,420
- CAT 5
- GEN $1.4M
- TOP1 31.3%
- PY 2024
Volume peers
Nearest volume peer: Olympus Corporation of the Americas ($5.2M)
SpringWorks Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for SpringWorks Therapeutics, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For SpringWorks Therapeutics, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 5 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $797.5K across 152 transactions, 58.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads SpringWorks Therapeutics, Inc.'s 5-category general-payment breakdown at $797.5K, 58.3% of the reported total.
SpringWorks Therapeutics, Inc. reports 5 general-payment categories - the top three are Compensation for Services Other Than Consulting (58.3%), Consulting Fee (23.0%), and Food and Beverage (8.7%). The remaining 2 categories make up 10.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How SpringWorks Therapeutics, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $797.5K | 152 | 58.3% |
| Consulting Fee | $313.9K | 104 | 23.0% |
| Food and Beverage | $118.6K | 3,835 | 8.7% |
| Grant | $75.5K | 14 | 5.5% |
| Travel and Lodging | $61.9K | 315 | 4.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $641,675.89 (46.9%) of $1,367,449.50 in this company's General Payments records across 2,444 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for SpringWorks Therapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Ut Md Anderson Cancer Center
$428,178.80 across 3 reported transactions
- 2
Noah C Federman
$89,990.61 across 103 reported transactions
- 3
Pedro Antonio Hermida de Viveiros
$59,244.66 across 147 reported transactions
- 4
Dipak Ramkumar
$37,377.41 across 79 reported transactions
- 5
Sajeve Thomas
$26,884.41 across 31 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
SpringWorks Therapeutics, Inc. ranks #264 of 1,925 by total payments (top 14% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #996 of 1,838 by HHI (bottom 46% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Monteris Medical Corporation : $197.5K total payments, HHI 1107
- Nuwellis, Inc. : $242.8K total payments, HHI 1104
- GM Pharmaceuticals, Inc. : $1.8K total payments, HHI 1093
- Flower Orthopedics Coporation : $381.4K total payments, HHI 1092
- Metric Medical Devices, Inc. : $10.9K total payments, HHI 1090
- CurvaFix, Inc. : $140.6K total payments, HHI 1090
- SpringWorks Therapeutics, Inc. (this company) : $1.4M total payments, HHI 1087
- Ion Beam Applications S.A. : $32.3K total payments, HHI 1083
- Cumberland Pharmaceuticals, Inc. : $341.4K total payments, HHI 1083
- Cook Incorporated : $6.0M total payments, HHI 1081
- Grifols Shared Services North America, Inc. : $105.0K total payments, HHI 1080
- BioCryst Pharmaceuticals, Inc. : $326.1K total payments, HHI 1076
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as SpringWorks Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about SpringWorks Therapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with SpringWorks Therapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Mitsubishi Tanabe Pharma America, Inc.
$5.2M 3,683 recipients
Compare payment profiles
BioXcel Therapeutics, Inc.
$5.2M 532 recipients
Compare payment profiles
KLS-Martin L.P.
$5.3M 6,287 recipients
Compare payment profiles
Actelion Pharmaceuticals US, Inc.
$5.2M 31,311 recipients
Compare payment profiles
Pacira Pharmaceuticals Incorporated
$5.4M 18,305 recipients
Compare payment profiles
Put this to use
SpringWorks Therapeutics, Inc. ranks #264 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where SpringWorks Therapeutics, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just SpringWorks Therapeutics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.